MCID: PRG002
MIFTS: 37

Progesterone-Receptor Positive Breast Cancer malady

Cancer category

Summaries for Progesterone-Receptor Positive Breast Cancer

Sources:
33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Progesterone-Receptor Positive Breast Cancer is related to estrogen-receptor positive breast cancer and estrogen-receptor negative breast cancer. An important gene associated with Progesterone-Receptor Positive Breast Cancer is ESR2 (estrogen receptor 2 (ER beta)), and among its related pathways are Plasma membrane estrogen receptor signaling and Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR2. The compounds 5fluorouracil and letrozole have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and breast, and related mouse phenotypes are endocrine/exocrine gland and integument.

Aliases & Classifications for Progesterone-Receptor Positive Breast Cancer

Sources:
8Disease Ontology
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer


Aliases & Descriptions:

progesterone-receptor positive breast cancer 8


External Ids:

Disease Ontology8 DOID:0060077

Related Diseases for Progesterone-Receptor Positive Breast Cancer

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the progesterone-receptor negative breast cancer family:

progesterone-receptor positive breast cancer

Diseases related to Progesterone-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 89)
idRelated DiseaseScoreTop Affiliating Genes
1estrogen-receptor positive breast cancer10.8
2estrogen-receptor negative breast cancer10.6
3progesterone-receptor negative breast cancer10.6
4her2-receptor positive breast cancer10.3
5vascular cancer10.3
6adenoma10.0ESR2
7leiomyosarcoma10.0PGR
8fibromatosis10.0PGR
9sertoli-leydig cell tumor10.0PGR
10colon adenocarcinoma10.0ESR2
11osteoarthritis10.0ESR2
12hemangioma10.0VEGFA
13leukemia10.0ESR2
14arthritis10.0ESR2
15cerebral meningioma10.0PGR
16insulin resistance10.0ESR2
17blindness10.0VEGFA
18azoospermia10.0ESR2
19hepatocellular carcinoma10.0VEGFA
20leydig cell tumor10.0CYP19A1
21cryptorchidism10.0CYP19A1
22alzheimer's disease10.0ESR2
23uterine carcinosarcoma10.0ERBB2
24aromatase deficiency10.0CYP19A1
25graves' disease10.0ESR2
26astrocytoma10.0VEGFA
27germ cell cancer10.0ESR2
28atherosclerosis10.0ESR2
29melanoma10.0VEGFA
30pituitary adenoma10.0ESR2
31polycystic ovary syndrome10.0ESR2, CYP19A1
32estrogen excess10.0CYP19A1, PGR
33rheumatoid arthritis10.0VEGFA, ESR2
34ovarian cyst10.0CYP19A1, ESR2
35diabetes mellitus10.0VEGFA, ESR2
36stomach cancer10.0ERBB2, VEGFA
37sertoli cell tumor10.0CYP19A1, PGR
38lung cancer10.0VEGFA, ERBB2
39ovarian cancer10.0ERBB2, PGR
40malignant mixed mullerian tumor10.0ERBB2, PGR
41male infertility10.0CYP19A1, ESR2
42pituitary tumors10.0ESR1, ESR2
43osteosarcoma10.0ESR2, ESR1
44progesterone resistance10.0PGR, ESR1
45choriocarcinoma10.0ESR2, CYP19A1
46bilateral breast cancer10.0ESR1, PGR
47prolactinoma10.0ESR2, ESR1
48smooth muscle tumor10.0ESR1, PGR
49retinopathy of prematurity10.0VEGFA
50lymphangioleiomyomatosis10.0ESR1, PGR

Graphical network of the top 20 diseases related to Progesterone-Receptor Positive Breast Cancer:



Diseases related to progesterone-receptor positive breast cancer

Clinical Features for Progesterone-Receptor Positive Breast Cancer

Drugs & Therapeutics for Progesterone-Receptor Positive Breast Cancer

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Progesterone-Receptor Positive Breast Cancer

Drug clinical trials:

Search ClinicalTrials for Progesterone-Receptor Positive Breast Cancer

Search NIH Clinical Center for Progesterone-Receptor Positive Breast Cancer

Search CenterWatch for Progesterone-Receptor Positive Breast Cancer

Genetic Tests for Progesterone-Receptor Positive Breast Cancer

Anatomical Context for Progesterone-Receptor Positive Breast Cancer

Sources:
33MalaCards
See all sources

MalaCards organs/tissues related to Progesterone-Receptor Positive Breast Cancer:

33
Skin, Lymph node, Breast, T cells, Endothelial

Animal Models for Progesterone-Receptor Positive Breast Cancer or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

Publications for Progesterone-Receptor Positive Breast Cancer

Sources:
51PubMed
See all sources

Articles related to Progesterone-Receptor Positive Breast Cancer:

(show all 31)
idTitleAuthorsYear
1
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. (23788750)
2013
2
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. (23579222)
2013
3
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. (23971947)
2013
4
A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. (22548922)
2012
5
Progesterone and levonorgestrel regulate expression of 17I^HSD-enzymes in progesterone receptor positive breast cancer cell line T47D. (22564730)
2012
6
Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. (21421521)
2011
7
A progesterone-receptor-positive huge retroperitoneal tumour mimics metastasis in a breast cancer patient: sarcomatoid renal cell carcinoma. (21618856)
2011
8
Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status? (21700456)
2011
9
Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. (21029696)
2010
10
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. (20705559)
2010
11
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. (19130322)
2009
12
Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. (19632824)
2009
13
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? (19703124)
2009
14
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. (18302747)
2008
15
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. (17581308)
2007
16
Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. (17293115)
2007
17
Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related. (16735717)
2006
18
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. (16467123)
2006
19
Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? (17189985)
2006
20
Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. (16467118)
2006
21
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. (16145046)
2005
22
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. (15563544)
2005
23
Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. (12556966)
2003
24
Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. (12408471)
2002
25
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. (9196144)
1997
26
Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. (9570382)
1997
27
Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. (8973592)
1996
28
A study on methodology and the criteria for positive immunohistostaining of estrogen and progesterone receptors in paraffin embedded sections of breast cancer]. (9388856)
1996
29
Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation. (7579503)
1995
30
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. (1634918)
1992
31
Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. (2334898)
1990

Genetic Variations for Progesterone-Receptor Positive Breast Cancer

Expression for genes affiliated with Progesterone-Receptor Positive Breast Cancer

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Progesterone-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Positive Breast Cancer.

Pathways for genes affiliated with Progesterone-Receptor Positive Breast Cancer

Sources:
38NCBI BioSystems Database, 12EMD Millipore, 52QIAGEN, 54Reactome, 50PharmGKB, 30KEGG
See all sources

Pathways related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show all 15)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.2ESR2, ESR1
2
Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR2
Hide members
9.2ESR2, ESR1
39.2ESR2, ESR1
4
Development Ligand-dependent activation of the ESR1/AP-1 pathway
Hide members
9.1ESR1, VEGFA
59.1CYP19A1, PGR, ESR2
6
Hide members
8.8PGR, ESR1, ESR2
7
Hide members
8.7ESR2, ESR1, CYP19A1
8
Development Endothelin-1/EDNRA signaling
Hide members
8.7VEGFA, ESR1, ESR2
9
Development Prolactin receptor signaling
Hide members
8.6ESR2, ESR1, ERBB2
10
Development Ligand-independent activation of ESR1 and ESR2
Hide members
8.6ESR2, ESR1, ERBB2
118.6VEGFA, CYP19A1, ESR1
12
Hide members
8.6ESR1, ERBB2, PGR
13
Hide members
8.5VEGFA, ERBB2, ESR1
148.5VEGFA, ERBB2, ESR1
158.1ESR2, ESR1, ERBB2, VEGFA

Compounds for genes affiliated with Progesterone-Receptor Positive Breast Cancer

Sources:
45Novoseek, 50PharmGKB, 60Tocris Bioscience, 11DrugBank, 24HMDB, 29IUPHAR, 2BitterDB
See all sources

Compounds related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show top 50)    (show all 142)
idCompoundScoreTop Affiliating Genes
15fluorouracil459.7PGR, ERBB2
2letrozole45 50 60 1112.3ERBB2, PGR, CYP19A1
3trilostane45 1110.1ESR1, ESR2, PGR
4idoxifene459.0PGR, CYP19A1, ESR1
55alpha-androstane-3alpha,17beta-diol459.0ESR2, ESR1, CYP19A1
6naringenin45 119.9CYP19A1, ESR1, ESR2
7vinorelbine45 119.9VEGFA, CYP19A1, ERBB2
8fadrozole458.8ESR1, CYP19A1, ERBB2
9tibolone458.8ESR1, CYP19A1, PGR
10danazol45 11 2410.8ESR1, PGR, CYP19A1
11capecitabine45 50 1110.8VEGFA, CYP19A1, PGR, ERBB2
12estradiol benzoate458.7CYP19A1, ESR1, ESR2, PGR
13nandrolone45 249.7CYP19A1, PGR, ESR1, ESR2
14leuprolide acetate458.7PGR, ESR2, ESR1, CYP19A1
15flutamide45 60 1110.7ESR1, CYP19A1, PGR
16bisphenol a458.7CYP19A1, ESR1, ESR2, PGR
17clomiphene citrate458.6PGR, CYP19A1, ESR1, ESR2
18levonorgestrel45 60 29 1111.6ESR2, ESR1, CYP19A1, PGR
19steroidal458.6ESR2, ESR1, PGR, CYP19A1
20diethylstilbestrol45 29 1110.6PGR, CYP19A1, ESR1, ESR2
2117beta-hydroxysteroid458.6PGR, ESR2, CYP19A1, ESR1
22progestins458.6PGR, CYP19A1, ESR2, ESR1
23estrone45 29 11 2411.5ESR2, ESR1, PGR, CYP19A1
24dihydrotestosterone45 29 11 2411.5ESR1, ESR2, PGR, CYP19A1
25megestrol acetate458.5ERBB2, PGR, CYP19A1, ESR1
26anastrozole45 119.5PGR, CYP19A1, ERBB2, ESR1
27lapatinib45 50 1110.4PGR, ESR1, ERBB2, CYP19A1
28geldanamycin45 50 60 1111.3PGR, ERBB2, ESR1, VEGFA
29cyclophosphamide45 50 1110.2PGR, ERBB2, ESR1, CYP19A1
30steroid458.2ESR1, ERBB2, CYP19A1
31mifepristone45 60 29 1111.1ESR1, CYP19A1, ESR2, PGR, VEGFA
32exemestane50 45 60 1111.1ERBB2, PGR, ESR1, ESR2, CYP19A1
33toremifene45 119.1ESR2, CYP19A1, ESR1, ERBB2, PGR
34fulvestrant45 50 29 1111.1ESR2, ESR1, ERBB2, CYP19A1, PGR
35raloxifene45 29 50 1111.1ESR1, CYP19A1, ESR2, ERBB2, PGR
364-hydroxytamoxifen458.1ESR2, CYP19A1, PGR, ERBB2, ESR1
37resveratrol45 60 11 2411.0VEGFA, ERBB2, ESR1, ESR2, PGR
38gefitinib45 50 1110.0ESR2, VEGFA, ESR1, ERBB2, CYP19A1
39gnrh458.0ESR1, CYP19A1, ESR2, PGR, ERBB2
40taxane458.0ERBB2, ESR1, PGR, CYP19A1, VEGFA
41trastuzumab45 50 1110.0ERBB2, PGR, CYP19A1, VEGFA, ESR1
42paraffin457.9ESR2, ERBB2, ESR1, PGR, VEGFA
43docetaxel45 50 60 1110.9PGR, ESR1, ERBB2, VEGFA, CYP19A1
44paclitaxel45 50 119.8CYP19A1, ERBB2, PGR, VEGFA, ESR1
45progesterone45 60 29 11 2411.6ESR1, ESR2, CYP19A1, PGR, ERBB2
46progestin457.6ERBB2, ESR2, ESR1, PGR, CYP19A1, VEGFA
47tamoxifen45 50 29 1110.5ESR2, ERBB2, ESR1, CYP19A1, PGR, VEGFA
48testosterone45 60 11 2410.5ESR1, ERBB2, PGR, CYP19A1, ESR2
49doxorubicin45 50 119.5ESR1, ERBB2, ESR2, PGR, CYP19A1, VEGFA
50genistein45 29 60 2 11 2412.5ESR1, ERBB2, ESR2, PGR, CYP19A1, VEGFA

GO Terms for genes affiliated with Progesterone-Receptor Positive Breast Cancer

Sources:
16Gene Ontology
See all sources

Biological processes related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1uterus developmentGO:0600659.5ESR2, ESR1
2vagina developmentGO:0600689.5ESR2, ESR1
3ovarian follicle developmentGO:0015419.4ESR2, VEGFA
4intracellular estrogen receptor signaling pathwayGO:0305209.4ESR1, ESR2
5positive regulation of cell adhesionGO:0457859.3VEGFA, ERBB2
6mammary gland alveolus developmentGO:0607499.3VEGFA, ESR1
7positive regulation of epithelial cell proliferationGO:0506799.3ERBB2, VEGFA
8androgen metabolic processGO:0082099.3CYP19A1, ESR1
9positive regulation of MAP kinase activityGO:0434069.0ERBB2, VEGFA
10transcription initiation from RNA polymerase II promoterGO:0063678.9PGR, ESR1, ESR2
11signal transductionGO:0071658.2ESR2, ESR1, ERBB2, PGR

Molecular functions related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activityGO:0048799.6ESR2, PGR
2estrogen response element bindingGO:0340569.3ESR2, ESR1
3estrogen receptor activityGO:0302849.2ESR1, ESR2
4core promoter sequence-specific DNA bindingGO:0010469.1ESR2, ESR1
5steroid bindingGO:0054968.9ESR2, ESR1, PGR
6steroid hormone receptor activityGO:0037078.9ESR2, ESR1, PGR
7enzyme bindingGO:0198998.5ESR2, ESR1, PGR

Products for genes affiliated with Progesterone-Receptor Positive Breast Cancer

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Progesterone-Receptor Positive Breast Cancer

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet